Abstract
nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant regimen in patients with early stage breast cancer. Patients with node-positive or high-risk node-negative early-stage breast cancer were eligible following completion of standard primary therapy. All the patients received four cycles, at 21-day intervals, of nab-paclitaxel (100 mg/m(2) IV days 1, 8, and 15) and cyclophosphamide (600 mg/m(2) IV day 1). HER2-positive patients also received trastuzumab 8 mg/kg IV on cycle 1 day 1, followed by 6 mg/kg every 21 days for a total of 52 weeks. The purpose of this trial was to evaluate feasibility and toxicity of this nab-paclitaxel-containing adjuvant regimen. 62 patients were treated between 2/08 and 11/08. The majority of the patients (87%) were HER2-negative. This adjuvant regimen was well tolerated, and full doses of all agents were administered in >90% of cycles. Grade 3/4 neutropenia occurred in 53% of the patients; however, only one episode of febrile neutropenia occurred in a total of 249 cycles administered. Other grade 3/4 adverse events occurred in less than 5% of pati...Continue Reading
References
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marjorie C GreenGabriel N Hortobagyi
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharJoyce O'Shaughnessy
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen E JonesLina Asmar
Apr 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew D SeidmanClifford Hudis
Apr 19, 2008·The New England Journal of Medicine·Joseph A SparanoNancy E Davidson
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JonesMichael A Savin
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharPaul Bhar
Citations
Aug 19, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Manabu MinamiHisanori Horiuchi
Jul 28, 2011·OncoTargets and Therapy·Yutaka YamamotoHirotaka Iwase
Nov 8, 2012·Breast Cancer : Basic and Clinical Research·W J Gradishar
Feb 25, 2014·Cancer Treatment Reviews·Christine MegerdichianSara A Hurvitz
Jul 23, 2014·Critical Reviews in Oncology/hematology·A ViúdezM Hidalgo
Mar 1, 2014·Expert Review of Anticancer Therapy·Eva Ciruelos, Christian Jackisch
Jun 20, 2015·Chemical Reviews·Yuanzeng MinAndrew Z Wang
Jul 6, 2015·Biochimica Et Biophysica Acta·Judith W J BergsFranz Rödel
Jul 31, 2014·International Journal of Clinical Oncology·Goro KutomiKoichi Hirata
Jun 19, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Denise A Yardley
Dec 3, 2014·Clinical Breast Cancer·Hideo ShigematsuMorihito Okada
Mar 19, 2015·Current Opinion in Oncology·Tu Nguyen-Ngoc, Eric Raymond
Mar 5, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Yan MaZhiyuan Hu
May 6, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·K Savitsky, X Yu